Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

335
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
335
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

256
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

333
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
Hepatitis01:25

Hepatitis

34
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

291
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
291
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.3K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Clinical outcomes of surgical management in 19 cases of tympanic paraganglioma].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2026
Same author

[Distribution of G6PD mutations and phenotypic characteristics in individuals with auditory neuropathy].

Zhonghua yi xue za zhi·2025
Same author

[Expression and clinical significance of CCL17, CCL22, and CCR4 in newly diagnosed multiple myeloma].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2024
Same author

[Clinical features and surgical treatment of right cardiac system tumors].

Zhonghua yi xue za zhi·2024
Same author

[Comparative study of laparoscopic Keyhole and Sugarbaker technique in the treatment of terminal paracolostomy hernia].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2023
Same author

[The progress of application of glucocorticoid in cochlear implantation].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2023

Related Experiment Video

Updated: Mar 24, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

8.0K

Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus.

L S Wu1, L C Jimmerson2, C E MacBrayne2

  • 1University of Southern California, Biomedical Engineering Los Angeles California USA.

CPT: Pharmacometrics & Systems Pharmacology
|March 3, 2016
PubMed
Summary

Ribavirin treatment can cause hemolytic anemia. This study models ribavirin exposure, red blood cell lifespan, and genetic factors to predict anemia severity and optimize dosing strategies for hepatitis C patients.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K

Related Experiment Videos

Last Updated: Mar 24, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

8.0K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K

Area of Science:

  • Pharmacology
  • Hematology
  • Genetics

Background:

  • Ribavirin is crucial for hepatitis C treatment but causes hemolytic anemia.
  • Understanding the ribavirin-anemia relationship is key for personalized dosing.
  • Red blood cell (RBC) production and lifespan are affected by ribavirin exposure.

Purpose of the Study:

  • To develop a quantitative model of ribavirin exposure and anemia.
  • To identify genetic factors influencing ribavirin-induced anemia.
  • To inform strategies for minimizing anemia in ribavirin therapy.

Main Methods:

  • Developed a pharmacokinetic/pharmacodynamic (PK/PD) model.
  • Incorporated RBC lifespan, anemia feedback, and hemoglobin decline.
  • Included genetic covariates: Inosine triphosphatase (ITPA) and Interleukin 28B (IL28B).

Main Results:

  • Model predicts anemia severity based on ITPA and IL28B genotypes.
  • Simulations show least anemia in IL28B non-CC/ITPA variant subjects.
  • Reducing ribavirin dose by 33-40% could halve grade 2 anemia incidence.

Conclusions:

  • A predictive model for ribavirin-induced anemia was established.
  • Genetic factors significantly modify anemia risk.
  • Model-guided dose reduction can mitigate anemia, improving treatment tolerability.